(Q34078483)

30 July 2017

1 reference

title

Nevirapine: pharmacokinetic considerations in children and pregnant women (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

1 reference

Mirochnick M

1

1 reference

30 July 2017

Clarke DF

series ordinal

2

1 reference

30 July 2017

Dorenbaum A

series ordinal

3

1 reference

30 July 2017

publication date

1 October 2000

1 reference

Clinical Pharmacokinetics

30 July 2017

published in

1 reference

30 July 2017

volume

39

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

281-293

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200039040-00004

30 July 2017

exact match

0 references

cites work

Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa

1 reference

12 December 2020

The duration of breastfeeding by HIV-1-infected mothers in developing countries: balancing benefits and risks

1 reference

12 December 2020

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

1 reference

12 December 2020

Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions.

1 reference

12 December 2020

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

1 reference

12 December 2020

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

1 reference

12 December 2020

Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

1 reference

12 December 2020

Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Preven

1 reference

12 December 2020

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

Short-course zidovudine for prevention of perinatal infection

1 reference

12 December 2020

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

1 reference

12 December 2020

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

1 reference

12 December 2020

Lack of pharmacokinetic interaction between nelfinavir and nevirapine

1 reference

12 December 2020

Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients

1 reference

12 December 2020

Nelfinavir and nevirapine interaction?

1 reference

12 December 2020

After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Tran

1 reference

12 December 2020

Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone

1 reference

12 December 2020

Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert

1 reference

12 December 2020

Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial

1 reference

12 December 2020

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

1 reference

12 December 2020

A Randomized, Double-Blind Trial on the Use of a Triple Combination Including Nevirapine, a Nonnucleoside Reverse Transcriptase HIV Inhibitor, in Antiretroviral-Naive Patients With Advanced Disease

1 reference

12 December 2020

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine

1 reference

12 December 2020

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

1 reference

12 December 2020

6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study G

1 reference

12 December 2020

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.

1 reference

12 December 2020

Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.

1 reference

12 December 2020

Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors

1 reference

12 December 2020

A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).

1 reference

12 December 2020

Methadone and antiretroviral medications, part I.

1 reference

12 December 2020

Breastfeeding by HIV-1-infected women and outcome in their infants: a cohort study from Durban, South Africa

1 reference

12 December 2020

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

1 reference

12 December 2020

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

12 December 2020

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

1 reference

12 December 2020

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

1 reference

12 December 2020

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

12 December 2020

Significant interactions with new antiretrovirals and psychotropic drugs.

1 reference

12 December 2020

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

1 reference

12 December 2020

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial

1 reference

12 December 2020

Risk of human immunodeficiency virus type 1 transmission through breastfeeding

1 reference

12 December 2020

Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1

1 reference

12 December 2020

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans

1 reference

12 December 2020

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587

1 reference

12 December 2020

Antiretroviral pharmacology in pregnant women and their newborns.

1 reference

12 December 2020

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group

1 reference

12 December 2020

Nevirapine: new drug, new class, new questions.

1 reference

12 December 2020

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

1 reference

12 December 2020

Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo

1 reference

12 December 2020

HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications

1 reference

12 December 2020

Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

10.2165/00003088-200039040-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1001684629

0 references

1 reference